~~<i id='7C405372FF'><strike id='7C405372FF'><tt id='7C405372FF'><pre id='7C405372FF'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：hotspot 2025-10-02 06:29:52 Page View：2

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： More hospitals are billing patients as online messages surge
Next article： How to save PrEP access — and even expand it

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

5:43RepublicanpresidentialcanditateAsaHutchinsonappearedon"GMA3"onJuly17,2023.ABCNewsFormerArkansasG

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

BridgeBio heart drug succeeds in pivotal study

AdobeAdrugdevelopedbythebiotechfirmBridgeBiototreatanincreasinglycommonheartconditionsucceededinitsm